Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
Twenty-one patients with relapsed or refractory acute myeloid leukemia (AML) were treated with mitoxantrone (12 mg/m2/day, days 1-3) and diaziquone (continuous infusion days 1-5). The dosage of diaziquone was increased for sequential cohorts of seven patients from 20 mg/m2/day to 24 mg/m2/day, and finally to 28 mg/m2/day to determine the maximum tolerated dose for this chemotherapy combination. Myelosuppression was the dose-limiting toxicity. The median time to recovery of blood counts was greater at the highest dose of diaziquone (48 days) than at the lower two doses (31 and 28 days). Other toxic effects were minimal. Overall, 9/21 (43%, 95% confidence interval, 0.22 to 0.66) patients achieved complete remission. We conclude that this combination of drugs shows sufficient antileukemic activity with acceptable toxicity to warrant further trials.
Hematology-Oncology Unit, Massachusetts General Hospital, Boston 02114.
P C
PC
Amrein
R B
RB
Davis
R J
RJ
Mayer
C A
CA
Schiffer
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001388:Aziridines / Q000009:adverse effects / Q000627:therapeutic use*; D016227:Benzoquinones; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D012074:Remission Induction; D016019:Survival Analysis; D013997:Time Factors
D001388:Aziridines; D016227:Benzoquinones; D008942:Mitoxantrone; C029108:diaziquone